Table III.
Breadth of anti-phospholipid mAb inhibition of HIV-1 infectivity against 12 R5 and X4 HIV-1 and SHIV primary isolates in the PBMC infectivity assay
| Primary HIV-1 isolates | mAbsa | Coreceptor usage | |||||
| IS4 | CL1 | P1 | PGN632 | anti-RSV | TriMabb | ||
| µg/ml | µg/ml | µg/ml | µg/ml | µg/ml | µg/ml | ||
| B.TORNO | 0.58 | 0.73 | 17 | 0.09 | >50 | 0.03 | CCR5 |
| B.PVO | 0.34 | 0.21 | 4.5 | 0.03 | >50 | 0.64 | CCR5 |
| B.6535 | 0.07 | 0.38 | 4.0 | <0.02 | >50 | 2.4 | CCR5 |
| C.DU123 | 0.06 | 0.19 | <0.02 | <0.02 | >50 | >25 | CCR5 |
| C.DU156 | 2.8 | 2.6 | 16 | 0.06 | >50 | >25 | CCR5 |
| C.DU151 | 3.1 | 1.1 | 1.2 | <0.02 | >50 | >25 | CCR5 |
| C.DU172 | 1.1 | 0.62 | 0.55 | <0.02 | >50 | >25 | CCR5 |
| SHIV 162P3 | 5.2 | 1.2 | 1.6 | <0.02 | >50 | 0.46 | CCR5 |
| SHIV 89.6P | >50 | >50 | >50 | >50 | >50 | 1.5 | CXCR4/CCR5 |
| A.92UG029 | >50 | >50 | >50 | >50 | >50 | >50 | CXCR4 |
| B.MN | >50 | >50 | >50 | >50 | >50 | 0.26 | CXCR4 |
| AE_01.NI1052 | >50 | >50 | >50 | >50 | >50 | >50 | CXCR4 |
a
mAbs are shown as IC80 values.
b
TriMab = equal concentration mixture of IgG1b12, 2F5, and 2G12.